Yakup Ergün, Medical Oncologist at Bower Hospital, shared on X:
“EGFR amplification in EGFR-mutant mNSCLC was associated with shorter PFS (11.6 vs 19.0 mo) and OS (34.0 vs 40.1) with 1L osimertinib, despite similar ORR.
The effect was most pronounced in EGFR exon 19 deletion, and MET alterations at resistance were more frequent (29% vs 12%)”
Title: Clinical significance of EGFR amplification in patients with EGFR-mutated metastatic non-small cell lung cancer receiving first-line osimertinib
Authors: Alessandro Di Federico, Federica Pecci, Mark Jeng, Marianna Peroni, Daniele Marinelli, Alessandro Leonetti, Sara Stumpo, Francesco Mantuano, Irene Zannini, Eleonora Gariazzo, Maisam Makarem, Amanda Pupo, Francesca Lo Bianco, Andrea De GiglioCorresponding Author, Dario de Biase, Annalisa Altimari, Elisa Gruppioni, Roberta Minari, Michela Verzè, Matteo Repetto, Francesca Sperandi, Barbara Melotti, Francesco Gelsomino, Lorenza Landi, Maristella Giammaruco, Stefano Scalera, Laura Cipriani, Marcello Maugeri‐Saccà, Nicola Calonaci, Giulio Caravagna, Biagio Ricciuti, Lynette M. Sholl, Soo Ryum Yang, Jaclyn LoPiccolo, Julia K. Rotow, Mark M. Awad, Federico Cappuzzo, Marcello Tiseo, Helena A. Yu, Pasi A. Janne, Andrea Ardizzoni
You might be interested in:
